Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

James Louis Januzzi Jr., M.D.

Co-Author

This page shows the publications co-authored by James Januzzi and Aaron Baggish.
Connection Strength

6.022
  1. New York Heart Association class versus amino-terminal pro-B type natriuretic peptide for acute heart failure prognosis. Biomarkers. 2010 Jun; 15(4):307-14.
    View in: PubMed
    Score: 0.438
  2. The differential diagnosis of an elevated amino-terminal pro-B-type natriuretic peptide level. Am J Cardiol. 2008 Feb 04; 101(3A):43-8.
    View in: PubMed
    Score: 0.373
  3. Amino-terminal pro-B-type natriuretic peptide testing and prognosis in patients with acute dyspnea, including those with acute heart failure. Am J Cardiol. 2008 Feb 04; 101(3A):49-55.
    View in: PubMed
    Score: 0.373
  4. A clinical and biochemical score for mortality prediction in patients with acute dyspnoea: derivation, validation and incorporation into a bedside programme. Heart. 2008 Aug; 94(8):1032-7.
    View in: PubMed
    Score: 0.366
  5. Hemoglobin and N-terminal pro-brain natriuretic peptide: Independent and synergistic predictors of mortality in patients with acute heart failure Results from the International Collaborative of NT-proBNP (ICON) Study. Clin Chim Acta. 2007 Jun; 381(2):145-50.
    View in: PubMed
    Score: 0.351
  6. Cost effectiveness of natriuretic peptide measurement in the primary care setting: have we found the gatekeeper for the evaluation of dyspneic outpatients? Congest Heart Fail. 2006 Mar-Apr; 12(2):108-9.
    View in: PubMed
    Score: 0.326
  7. A validated clinical and biochemical score for the diagnosis of acute heart failure: the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Acute Heart Failure Score. Am Heart J. 2006 Jan; 151(1):48-54.
    View in: PubMed
    Score: 0.323
  8. A clinical and biochemical critical pathway for the evaluation of patients with suspected acute congestive heart failure: The ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) algorithm. Crit Pathw Cardiol. 2004 Dec; 3(4):171-6.
    View in: PubMed
    Score: 0.299
  9. Postoperative troponin-T predicts prolonged intensive care unit length of stay following cardiac surgery. Crit Care Med. 2004 Sep; 32(9):1866-71.
    View in: PubMed
    Score: 0.294
  10. Systematic Evaluation of Endothelin 1 Measurement Relative to Traditional and Modern Biomarkers for Clinical Assessment and Prognosis in Patients With Chronic Systolic Heart Failure: Serial Measurement and Multimarker Testing. Am J Clin Pathol. 2017 May 01; 147(5):461-472.
    View in: PubMed
    Score: 0.177
  11. Concentrations of highly sensitive cardiac troponin-I predict poor cardiovascular outcomes and adverse remodeling in chronic heart failure. J Cardiovasc Transl Res. 2015 Apr; 8(3):164-72.
    View in: PubMed
    Score: 0.153
  12. Galectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunction. Am Heart J. 2015 Mar; 169(3):404-411.e3.
    View in: PubMed
    Score: 0.151
  13. Prognostic usefulness of insulin-like growth factor-binding protein 7 in heart failure with reduced ejection fraction: a novel biomarker of myocardial diastolic function? Am J Cardiol. 2014 Nov 15; 114(10):1543-9.
    View in: PubMed
    Score: 0.147
  14. Measurement of novel biomarkers to predict chronic heart failure outcomes and left ventricular remodeling. J Cardiovasc Transl Res. 2014 Mar; 7(2):250-61.
    View in: PubMed
    Score: 0.140
  15. Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. Eur J Heart Fail. 2013 Oct; 15(10):1157-63.
    View in: PubMed
    Score: 0.134
  16. Characterization and prediction of natriuretic peptide "nonresponse" during heart failure management: results from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) and the NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death (BATTLESCARRED) study. Congest Heart Fail. 2013 May-Jun; 19(3):135-42.
    View in: PubMed
    Score: 0.131
  17. Improvement in structural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides: mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study. Eur J Heart Fail. 2013 Mar; 15(3):342-51.
    View in: PubMed
    Score: 0.130
  18. Heart failure outcomes and benefits of NT-proBNP-guided management in the elderly: results from the prospective, randomized ProBNP outpatient tailored chronic heart failure therapy (PROTECT) study. J Card Fail. 2012 Aug; 18(8):626-34.
    View in: PubMed
    Score: 0.126
  19. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol. 2011 Oct 25; 58(18):1881-9.
    View in: PubMed
    Score: 0.121
  20. Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study. Am Heart J. 2010 Apr; 159(4):532-538.e1.
    View in: PubMed
    Score: 0.108
  21. Soluble ST2 plasma concentrations predict 1-year mortality in acutely dyspneic emergency department patients with pulmonary disease. Am J Clin Pathol. 2008 Oct; 130(4):578-84.
    View in: PubMed
    Score: 0.098
  22. Clinical uncertainty, diagnostic accuracy, and outcomes in emergency department patients presenting with dyspnea. Arch Intern Med. 2008 Apr 14; 168(7):741-8.
    View in: PubMed
    Score: 0.095
  23. Usefulness of aminoterminal pro-brain natriuretic peptide testing for the diagnostic and prognostic evaluation of dyspneic patients with diabetes mellitus seen in the emergency department (from the PRIDE Study). Am J Cardiol. 2007 Nov 01; 100(9):1336-40.
    View in: PubMed
    Score: 0.090
  24. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol. 2007 Aug 14; 50(7):607-13.
    View in: PubMed
    Score: 0.090
  25. Association of atrial fibrillation and amino-terminal pro-brain natriuretic peptide concentrations in dyspneic subjects with and without acute heart failure: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Am Heart J. 2007 Jan; 153(1):90-7.
    View in: PubMed
    Score: 0.086
  26. Combination of D-dimer and amino-terminal pro-B-type natriuretic Peptide testing for the evaluation of dyspneic patients with and without acute pulmonary embolism. Arch Pathol Lab Med. 2006 Sep; 130(9):1326-9.
    View in: PubMed
    Score: 0.085
  27. Neither race nor gender influences the usefulness of amino-terminal pro-brain natriuretic peptide testing in dyspneic subjects: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. J Card Fail. 2006 Aug; 12(6):452-7.
    View in: PubMed
    Score: 0.084
  28. NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) echocardiographic substudy. Eur Heart J. 2006 Apr; 27(7):839-45.
    View in: PubMed
    Score: 0.082
  29. Amino-terminal pro-brain natriuretic peptide for the diagnosis of acute heart failure in patients with previous obstructive airway disease. Ann Emerg Med. 2006 Jul; 48(1):66-74.
    View in: PubMed
    Score: 0.081
  30. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med. 2006 Feb 13; 166(3):315-20.
    View in: PubMed
    Score: 0.081
  31. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol. 2006 Jan 03; 47(1):91-7.
    View in: PubMed
    Score: 0.080
  32. Combined use of amino terminal-pro-brain natriuretic peptide levels and QRS duration to predict left ventricular systolic dysfunction in patients with dyspnea. Am J Cardiol. 2005 Jul 15; 96(2):263-6.
    View in: PubMed
    Score: 0.078
  33. The effects of ejection fraction on N-terminal ProBNP and BNP levels in patients with acute CHF: analysis from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. J Card Fail. 2005 Jun; 11(5 Suppl):S9-14.
    View in: PubMed
    Score: 0.077
  34. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005 Apr 15; 95(8):948-54.
    View in: PubMed
    Score: 0.077
  35. Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. Am Heart J. 2005 Apr; 149(4):744-50.
    View in: PubMed
    Score: 0.077
  36. Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy. JACC Heart Fail. 2013 Dec; 1(6):480-7.
    View in: PubMed
    Score: 0.035
  37. Images in cardiovascular medicine. Acute reversible stress-induced cardiomyopathy associated with cesarean delivery under spinal anesthesia. Circulation. 2008 Jun 10; 117(23):3052-3.
    View in: PubMed
    Score: 0.024
  38. Amino-terminal pro-brain natriuretic Peptide, renal function, and outcomes in acute heart failure: redefining the cardiorenal interaction? J Am Coll Cardiol. 2006 Oct 17; 48(8):1621-7.
    View in: PubMed
    Score: 0.021
  39. Ischemia-modified albumin improves the usefulness of standard cardiac biomarkers for the diagnosis of myocardial ischemia in the emergency department setting. Am J Clin Pathol. 2005 Jan; 123(1):140-5.
    View in: PubMed
    Score: 0.019
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.